Nicholas Hornstein, Assistant Professor at Northwell Health, shared on X:
“New FDA approval for metastatic anal cancer.
Retifanlimab + Carbo-Pac brings anti-PDL1 into the front-line metastatic setting.
mOS 29 vs 23 months
ORR 56% vs 44%Based off POD1UM-303. Great randomized study in a rare disease!”
An impactful article on Anal Cancer.
